Prot #M19-753: A Phase 1 Open-Label Study Evaluating the Safety and Tolerability, and Pharmacokinetics of Navitoclax Monotherapy and in Combination with Ruxolitinib in Myeloproliferative Neoplasm Subjects

Project: Research project

Project Details

StatusFinished
Effective start/end date6/18/21 → 6/18/22

Funding

  • AbbVie Inc. (Prot #M19-753)